The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: Randomized controlled clinical trial
Hassan, S., Hassan, A., Mohamed, M., Al Ashram, M., Nesim, M., Allam, M. (2024). The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: Randomized controlled clinical trial. EKB Journal Management System, (), -. doi: 10.21608/mid.2024.281579.1877
Samar Osama Hassan; Ahmed Nour El-Din Hassan; Manal Sabry Mohamed; Mohamed Nabil Badawy Al Ashram; Mina Michael Nesim; Mohamed Farouk Allam. "The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: Randomized controlled clinical trial". EKB Journal Management System, , , 2024, -. doi: 10.21608/mid.2024.281579.1877
Hassan, S., Hassan, A., Mohamed, M., Al Ashram, M., Nesim, M., Allam, M. (2024). 'The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: Randomized controlled clinical trial', EKB Journal Management System, (), pp. -. doi: 10.21608/mid.2024.281579.1877
Hassan, S., Hassan, A., Mohamed, M., Al Ashram, M., Nesim, M., Allam, M. The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: Randomized controlled clinical trial. EKB Journal Management System, 2024; (): -. doi: 10.21608/mid.2024.281579.1877

The effects of probiotic Lactobacillus acidophilus and colchicine on the control of symptoms, duration, and disease progression of mild and moderate cases of COVID-19: Randomized controlled clinical trial

Microbes and Infectious Diseases
Articles in Press, Accepted Manuscript, Available Online from 28 April 2024  XML
Document Type: Original Article
DOI: 10.21608/mid.2024.281579.1877
View on SCiNiTO View on SCiNiTO
Authors
Samar Osama Hassan email 1; Ahmed Nour El-Din Hassan2, 3; Manal Sabry Mohamed4; Mohamed Nabil Badawy Al Ashram4; Mina Michael Nesim4; Mohamed Farouk Allamorcid 1
1Family Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2Clinical Pharmacology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
3Clinical Pharmacology Department, Faculty of Medicine, Galala University, Egypt
4Internal Medicine department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a newly emerging human disease caused by a novel coronavirus, causing a global pandemic crisis. Probiotics and/or colchicine may be considered as options for treatment since they have anti-viral, anti-inflammatory, and immunomodulatory effects. Results: A total of 150 patients with mild and moderate severity of COVID-19 were enrolled in the study, 50 patients in each arm; around one third (34.7%) of the participants were aged between 29 and 39 years; one-quarter (24.7%) were aged between 18 and 28 years and 40.6% were aged 40 years and above. The mean duration of symptoms improvement was 12, 11 and 12 in the colchicine, probiotic, and control groups, respectively. Improvement of inflammatory markers over time occurred in each of the three groups, with no statistically significant difference between them. Conclusion: Probiotic Lactobacillus acidophilus and colchicine shows no significant effect on the symptoms, duration, and progression of mild and moderate cases of COVID-19.
Keywords
COVID-19; RCT; Ain Shams University; Cairo
Statistics
Article View: 30